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Heart Failure With Preserved Ejection Fraction
Is Characterized by Dynamic Impairment of Active
Relaxation and Contraction of the Left Ventricle on
Exercise and Associated With Myocardial Energy Deficiency
Thanh T. Phan, MB, CHB (HONS),* Khalid Abozguia, MBBCH,* Ganesh Nallur Shivu, MBBS,*
Gnanadevan Mahadevan, MBBS,* Ibrar Ahmed, MB, CHB,* Lynne Williams, MB, CHB,*
Girish Dwivedi, MBBS,* Kiran Patel, PHD,* Paul Steendijk, PHD,† Houman Ashrafian, MA,‡
Anke Henning, PHD,§ Michael Frenneaux, MD*
Birmingham and Oxford, United Kingdom; Leiden, the Netherlands; and Zurich, Switzerland
Objectives We sought to evaluate the role of exercise-related changes in left ventricular (LV) relaxation and of LV contractile
function and vasculoventricular coupling (VVC) in the pathophysiology of heart failure with preserved ejection
fraction (HFpEF) and to assess myocardial energetic status in these patients.
Background To date, no studies have investigated exercise-related changes in LV relaxation and VVC as well as in vivo myo-
cardial energetic status in patients with HFpEF.
Methods We studied 37 patients with HFpEF and 20 control subjects. The VVC and time to peak LV filling (nTTPF, a mea-
sure of LV active relaxation) were assessed while patients were at rest and during exercise by the use of radionu-
clide ventriculography. Cardiac energetic status (creatine phosphate/adenosine triphosphate ratio) was assessed
by the use of 31P magnetic resonance spectroscopy at 3-T.
Results When patients were at rest, nTTPF and VVC were similar in patients with HFpEF and control subjects. The cardiac
creatine phosphate/adenosine triphosphate ratio was reduced in patients with HFpEF versus control subjects
(1.57  0.52 vs. 2.14  0.63; p  0.003), indicating reduced energy reserves. Peak maximal oxygen uptake
and the increase in heart rate during maximal exercise were lower in patients with HFpEF versus control subjects
(19  4 ml/kg/min vs. 36  8 ml/kg/min, p  0.001, and 52  16 beats/min vs. 81  14 beats/min,
p  0.001). The relative changes in stroke volume and cardiac output during submaximal exercise were lower in
patients with HFpEF versus control subjects (ratio exercise/rest: 0.99  0.34 vs. 1.25  0.47, p  0.04, and
1.36  0.45 vs. 2.13  0.72, p  0.001). The nTTPF decreased during exercise in control subjects but in-
creased in patients with HFpEF (0.03  12 s vs. 0.07  0.11 s; p  0.005). The VVC decreased on exercise
in control subjects but was unchanged in patients with HFpEF (0.01  0.15 vs. 0.25  0.19; p  0.001).
Conclusions Patients with HFpEF have reduced cardiac energetic reserve that may underlie marked dynamic slowing of LV
active relaxation and abnormal VVC during exercise. (J Am Coll Cardiol 2009;54:402–9) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.012(
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there is increasing consensus that approximately 50% of
atients with the clinical features of chronic heart failure
xperience heart failure with preserved ejection fraction
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Manuscript received December 26, 2008; revised manuscript received April 20,
009, accepted May 5, 2009.HFpEF) (1). Epidemiological observations of different pop-
lations confirm that the prevalence of HFpEF is increasing as
t tracks the demographic transition, especially in obese hyper-
ensive women (2). HFpEF causes as many hospitalizations
See page 419
nd incurs as severe a rate of morbidity as heart failure with
educed left ventricular ejection fraction (LVEF). Finally,
FpEF portends a significant and unimproving rate of mor-
ality (3). Nonetheless, despite its unarguable clinical signifi-
ance, the pathophysiology of HFpEF remains controversial,
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July 28, 2009:402–9 LV Dynamic Abnormalities in HFpEFith some investigators (4) proposing that diastolic abnormal-
ties and others (5) proposing that systolic abnormalities play a
ominant role. However, although most studies have focused
n the parameters of patients at rest, symptoms predominantly
ccur during exercise (4,6). One study (7) reported a dynamic
mpairment of left ventricular (LV) active relaxation during
sometric (handgrip) exercise, but the relevance of this obser-
ation to dynamic leg exercise that usually provokes breathless-
ess during everyday life is unclear.
The present study was designed to test the hypothesis
hat exercise limitation in HFpEF is due to a dynamic
mpairment of LV active relaxation and LV contractile
erformance during exercise, both of which may be due to
n underlying impaired myocardial energetic reserve. We
sed radionuclide ventriculography to measure LV active
elaxation, LV contractile function, and vasculoventricular
oupling (VVC) at rest and during exercise. Furthermore,
1P cardiac magnetic resonance spectroscopy (MRS) at 3-T
as used to measure in vivo myocardial energetics.
ethods
atients. We studied 37 patients with HFpEF who were
rospectively recruited from heart failure clinics. We also
tudied 20 healthy control subjects with no cardiac history
r diabetes mellitus. Study participants had clinical exami-
ation, 12-lead electrocardiogram, pulmonary function test,
chocardiogram, metabolic exercise test, and radionuclide
entriculography studies, and a subgroup underwent 31P
ardiac MRS studies to assess cardiac energetic status. All
ontrol subjects had a normal cardiovascular examination,
2-lead electrocardiogram, and echocardiogram.
Patients with HFpEF were defined in accordance with
merican College of Cardiology/American Heart Associa-
ion recommendations (8) as follows: 1) symptoms and signs
f heart failure; 2) ejection fraction (EF) 50%; and 3) no
alvular abnormalities. In addition, we stipulated that pa-
ients should have: 4) a maximal oxygen uptake (VO2max)
80% of age- and sex-predicted values with a pattern of gas
xchange on metabolic exercise testing indicating a cardiac
ause for limitation; and 5) the absence of objective evidence
f lung disease on formal lung function testing and/or
bsence of arterial desaturation during exercise and with a
entilatory reserve 15 l at peak exercise.
We chose to use such a definition as advocated by Coats
t al. (9) to have robust evidence that patients had exercise
imitation that was cardiac rather than noncardiac in origin
nd so as not to prejudge the underlying pathophysiology by
tipulating the presence of resting diastolic abnormalities
ecause diastolic abnormalities frequently are present in
ealthy elderly subjects (10) and do not necessarily predict
linical heart failure (11) or exertional dyspnea (12). Patients
ith rhythm other than sinus were excluded. The investi-
ations were performed at The University of Birmingham
ith approval of the Research Ethics Committee. Informedonsent was obtained from all patients and control subjects. schocardiography. Echocar-
iography was performed with
articipants in the left lateral de-
ubitus position with a Vivid 7
chocardiographic machine (GE,
ilwaukee, Wisconsin) by the
se of a 2.5-MHz transducer.
ardiac quantifications were de-
ermined in accordance with the
uropean Association of Echo-
ardiography (13). Left ventricu-
ar end-systolic elastance, a rela-
ively load-independent measure
f LV contractility, was deter-
ined by use of the noninvasive
ingle-beat technique (14). Arte-
ial elastance, a measure of the
tiffness of the entire arterial tree,
as calculated as the ratio of LV
nd-systolic pressure/stroke vol-
me. Studies were stored digi-
ally and analyzed offline.
RS. In vivo myocardial ener-
etics were measured by 31P car-
iac MRS at 3-T as previously
alidated and described in detail
y our group (15). We performed MRS by using a Phillips
chieva 3 scanner (Da Best, the Netherlands) and a linearly
olarized transmitter and receiver 31P coil with a diameter
f 14 cm. The repetition time was 10,000 ms with 136
verages and 512 samples. Acquisition was electrocardio-
ram gated, and the trigger delay was set to acquire in
iastole. Total scan time was 23 min. Java magnetic reso-
ance user interface version 3.0 (jMRUI, developed by A.
an den Boogaart, Katholieke Universiteit Leuven, Leuven,
elgium) was used for analysis (16). Creatine phosphate
PCr) and gamma-adenosine triphosphate (ATP) were used
o determine the PCr/ATP ratio, which is a measure of
ardiac energetic state (17).
Patients with ischemic heart disease and diabetes (n  7)
ere excluded from the MRS studies because these condi-
ions are known to have impaired cardiac energetics (17,18).
atients with contraindications were also excluded from the
RS study (n  5). The spectra of 1 patient were excluded
rom the analysis because of their poor quality. Three
ontrol subjects had contraindications to the MRS study.
ata were analyzed separately by an investigator who was
naware of participants’ clinical status.
adionuclide ventriculography. The LVEF and diastolic
lling were assessed by the use of radionuclide ventriculog-
aphy with the patient at rest and during graded semierect
xercise on a cycle ergometer as previously described in
etail by our group (19,20). Three minutes of data were
cquired at rest and during exercise after a 30-s period for
tabilization of heart rate at the commencement of each
Abbreviations
and Acronyms
ATP  adenosine
triphosphate
HFpEF  heart failure with
preserved ejection fraction
HR  heart rate
LV  left ventricular
LVEF  left ventricular
ejection fraction
MRS  magnetic
resonance spectroscopy
nTTPF  time to peak left
ventricular filling
PCr  creatine phosphate
PKA  protein kinase A
SVI  stroke volume index
TDI  tissue Doppler
imaging
TnI  troponin I
VO2max  maximal oxygen
uptake
VVC  vasculoventricular
couplingtage. Exercise was performed at 50% workloads of heart
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LV Dynamic Abnormalities in HFpEF July 28, 2009:402–9ate reserve. Data were analyzed by the use of LinkMedical
APS software (Sun Microsystems, Hampshire, United
ingdom).
Peak left ventricular filling rate in terms of end-diastolic
ount per second and time to peak filling normalized for
-R interval (nTTPF) in milliseconds after end-systole
ere calculated from the first derivative of the diastolic
ctivity-time curve. Venous blood samples were obtained for
eighing and for counting of blood gamma activity during
ach scan to correct for physical and physiological decay as
ell as for determination of relative volume changes (21).
he validity of these radionuclide measures of diastolic filling
t high heart rates has been established previously (22).
All gated blood pool scan-derived volumes were normal-
zed to body surface area, yielding their respective indexes:
nd-diastolic volume index, end-systolic volume index,
troke volume index (SVI), and cardiac index. The follow-
ng indexes were calculated: 1) arterial elastance index 
nd-systolic pressure (ESP) SVI; 2) LV end-systolic elas-
ance index  ESP/end-systolic volume index; and 3) VVC
atio  arterial elastance index/LV end-systolic elastance
ndex  (1/EF) – 1 (23).
etabolic exercise test. All participants underwent a
ymptom-limited erect treadmill exercise with simultaneous
espiratory gas analysis. The incremental ramp protocol was
uch that the speed and inclination increased in a stepwise
anner every minute. Exercise was terminated at the
ubject’s request because of fatigue or breathlessness.
O2max was obtained during peak exercise.
tatistics. Continuous variables are expressed as mean 
D. An unpaired Student t test (2-tailed) was used to assess
ifferences between mean values. Categorical variables were
ompared with the Pearson chi-square test. All reported
values were calculated on the basis of 2-sided tests, and a
value 0.05 was considered to indicate statistical signif-
cance. Variances of datasets were determined by the use of
he Levene test. SPSS (version 15.0, SPSS Inc., Chicago,
llinois) was used to perform the statistical operations.
esults
haracteristics of the patients. Patients with HFpEF
ere generally female, overweight, and 67  9 years of age
ith a history of hypertension; however, the blood pressure
f these patients was well treated (systolic blood pressure
38  19 mm Hg vs. 131  23 mm Hg; p  0.23, in
atients with HFpEF vs. control subjects) (Table 1). The
issue Doppler mitral E-wave velocity-E= tissue velocity at
he basal anterolateral (a measure of LV end-diastolic
ressure) (24) was significantly greater in patients with
FpEF than in control subjects. There was also a trend
nonsignificant) to greater end-systolic elastance in pa-
ients with HFpEF than in the control group. Patients
ith HFpEF also had significantly reduced VO2max and
educed peak heart rate (HR) on metabolic exercise
esting. During semierect cycle exercise, the relative ttroke volume (SViEXERCISE/SViREST) was lower in pa-
ients with HFpEF compared with control subjects (0.99 
.34 vs. 1.25  0.47; p  0.04), and relative cardiac
utput (COiEXERCISE/COiREST) was also lower (1.36 
.45 vs. 2.13  0.72; p  0.001) (Table 2).
eft ventricular active relaxation. The nTTPF is deter-
ined by the rate of LV active relaxation (25) and by
ransmitral pressure gradient at the time of mitral valve
pening. The nTTPF was similar at rest in patients with
FpEF and in control subjects. During exercise, it short-
ned in control subjects but lengthened in patients with
FpEF (Table 2). Furthermore, peak filling rates during
xercise were significantly reduced in patients with HFpEF
ompared with control subjects (Table 2).
eft ventricular contractile function and VVC. The
VC was similar at rest in patients with HFpEF and in
ontrol subjects. During exercise, LV arterial elastance, a
easure of the stiffness of the entire arterial tree, in-
reased in both patients with HFpEF and control sub-
ects but tended to increase more in patients with
FpEF. The LV end-systolic elastance, a measure of LV
ontractile function, markedly increased during exercise
n control subjects but increased substantially less in
atients with HFpEF. Accordingly, the VVC ratio was
ssentially unchanged during exercise in patients with
FpEF but decreased substantially on exercise in healthy
ontrol subjects. Furthermore, although resting LVEF
nd peak emptying rate were similar in patients with
FpEF and in control subjects, during exercise both
ere lower in patients with HFpEF (Table 2).
n vivo myocardial energetic state. At rest, the cardiac
Cr/ATP ratio in patients with HFpEF was significantly
educed compared with healthy control subjects at 1.57 
.52 and 2.14  0.63, respectively, p  0.003 (Fig. 1).
iscussion
he principal findings of this study are as follows: 1) patients
ith HFpEF manifest a significant reduction in PCr/ATP
atio at rest, indicating impairment of myocardial energy
reserves.” 2) As a corollary, during exercise, the energeti-
ally demanding active relaxation stage of diastole length-
ned in patients with HFpEF (vs. a shortening in control
ubjects), and there was also a failure of the normal increase
n contractile function on exercise in patients with HFpEF.
hese combined dynamic abnormalities of both diastolic
nd contractile function together resulted in a lower stroke
olume during exercise. 3) Consistent with previous studies,
FpEF patients with HFpEF demonstrated chronotropic
ncompetence on exercise (26). These findings underline the
mportance of a dynamic (rather than resting) assessment of
ardiac function to comprehensively characterize patients
ith HFpEF.
The pathophysiology of HFpEF has been the subject of
onsiderable controversy. These patients typically are hyper-
ensive and exhibit impaired LV active relaxation and/or
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July 28, 2009:402–9 LV Dynamic Abnormalities in HFpEFncreased passive LV diastolic stiffness at rest (4). This
nding has led some authors (27) to conclude that exercise
imitation is primarily a result of impaired LV diastolic
lling and to the use of the term diastolic heart failure.
owever, diastolic dysfunction is also a common finding at
est in healthy elderly subjects (10). Furthermore, subtle
bnormalities of systolic function, in particular long-axis
Baseline Characteristics of the SubjectsTable 1 Baseline Characteristics of the Sub
Variable
Pati
Age, yrs
Female sex
Body mass index, kg/m2
Left ventricular hypertrophy
Diabetes mellitus
Hypertension
Ischemic heart disease
New York Heart Association functional class
II
III
Drug therapy
Diuretic
ACE inhibitor
ARB
Beta-blocker
Calcium blocker
Alpha blocker
Spironolactone
Nitrate
Metabolic exercise testing
VO2max (ml/kg/min)
Respiratory exchange ratio
Breathing reserve, l/min
HR, beats/min
Rest
Peak exercise
HR
SBP, mm Hg
Rest
Peak exercise
DBP, mm Hg
Rest
Peak exercise
Echocardiography
Left ventricular ejection fraction, %
Mitral E-wave velocity, m/s
Mitral A-wave velocity, m/s
Ratio of E-wave/A-wave velocity
Mitral E-wave deceleration, ms
E/E’ (lateral)
Ees
Ea
Values are n (%), n, or mean SD. When patients on beta-blockers w
resting heart rate (HR) (p  0.14). The body mass index (BMI) is the w
ACE  angiotensin-converting enzyme; ARB  angiotensin II recep
mitral E-wave velocity-E= tissue velocity (PW-TDI) at basal anterior-lat
failure with preserved ejection fraction; LA left atrium; MABPmean
blood pressure; VO2max  maximal oxygen uptake.ystolic function, are also almost universally observed in patients with HFpEF despite normal LVEF (5). This
nding has led others (28) to propose that HFpEF is
redominantly a disorder of contractile function. To com-
are both of these possibilities, we specifically chose to
efine the syndrome on the basis of a limitation of exercise
apacity with a cardiac basis for this limitation rather than
y using resting parameter of diastolic function so as to not
ith HFpEF
37)
Control Subjects
(n  20) p Value
9 63 7 0.51
(76) 10 (50) 0.05
4 26 5 0.01
(51) 5 (25) 0.05
(11) 0 —
(73) 0 —
(11) 0 —
9 0 —
8 0 —
(27) 0 —
(54) 0 —
(16) 0 —
(22) 0 —
(27) 0 —
(11) 0 —
(5) 0 —
(8) 0 —
4 36 8 0.001
0.07 1.13 0.10 0.003
15 43 18 0.16
14 83 17 0.03
20 166 11 0.001
16 81 14 0.001
19 131 23 0.23
26 190 30 0.30
11 181 12 0.98
13 84 10 0.36
14 63 6 0.77
0.19 0.61 0.12 0.02
0.20 0.59 0.17 0.001
0.35 1.03 0.32 0.47
70 269 73 0.82
4 8 2 0.001
1.07 2.60 0.53 0.09
0.63 2.28 0.48 0.69
luded from analysis, the levels of significance was similar apart from
n kilograms divided by the square of the height in meters.
ker; DBP  diastolic blood pressure; Ea  arterial elastance; E/E= 
ll ratio; Ees  left ventricular end-systolic elastance; HFpEF  heart
l blood pressure; NYHA New York Heart Association; SBP systolicjects
ents W
(n 
67
28
30
19
4
27
4
2
10
20
6
8
10
4
2
3
19
1.06
36
74
127
52
138
182
181
81
64
0.72
0.80
0.96
274
12
3.07
2.22
ere exc
eight i
tor bloc
eral warejudge the role of diastolic versus systolic mechanisms.
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LV Dynamic Abnormalities in HFpEF July 28, 2009:402–9Little attention has been paid to changes in systolic and
iastolic function during dynamic exercise, which is when
ost patients experience their symptoms. In one study, 10
atients with HFpEF were assessed with invasive pressure-
olume loops and compared with age-matched control
ubjects (7). The former had increased arterial elastance (a
easure of the stiffness of the entire arterial tree) and
ncreased LV end-systolic elastance (a measure of the
tiffness of the ventricle during systole and a relatively load
ndependent measure of the contractile state of the left
entricle) (29). Although diastolic abnormalities were not
niversally present in patients at rest, marked differences
ppeared during handgrip exercise. The rate of LV active
elaxation increased in healthy subjects but it slowed in
atients with HFpEF (7). In another study from the same
roup, exercise-related symptoms in Afro-Caribbean hyper-
ensive patients appeared to be strongly associated with
hronotropic incompetence and an inadequate vasodilator
adionuclide Ventriculography at Rest and onxercise: Diastolic Fil ing Char cteri ics, Systolicunct on, R laxation, Stiffness, and VVC
Table 2
Radionuclide V ntri ulography at Rest and on
Exercise: Diastolic Filling Characteristics, Systolic
Function, Relaxation, Stiffness, and VVC
Variable
Patients With HFpEF
(n  37)
Control Subjects
(n  20) p Value
Exercise HR, beats/min 97 14 114 11 0.001
Exercise SBP, mm Hg 204 26 198 27 0.45
Exercise DBP, mm Hg 95 15 97 7 0.56
Exercise MABP, mm Hg 132 15 131 9 0.85
Ejection fraction, %
Rest 65 9 64 9 0.61
Exercise 66 9 72 8 0.05
Peak emptying rates, EDC/s
Rest 382 106 400 90 0.56
Exercise 477 123 563 144 0.04
Peak filling rates, EDC/s
Rest 342 120 321 111 0.54
Exercise 504 127 602 163 0.02
Time to peak filling, RR
Rest 0.18 0.08 0.18 0.09 0.84
Exercise 0.25 0.09 0.16 0.08 0.001
 nTTPF 0.07 0.11 0.03 0.12 0.005
VVC ratio, EaI/ELVI
Rest 0.57 0.20 0.62 0.22 0.36
Exercise 0.55 0.19 0.41 0.15 0.01
 VVC 0.01 0.15 0.25 0.19 0.001
Relative exercise  stroke
volume index
0.99 0.34 1.25 0.47 0.04
Relative exercise  cardiac
output index
1.36 0.45 2.13 0.72 0.001
Relative exercise  ELVI 1.35 0.50 1.85 0.63 0.01
Relative exercise  EaI 1.52 0.48 1.28 0.44 0.17
alues are mean SD. When patients on beta-blockers were excluded from analysis, the levels of
ignificance were similar apart from peak filling rates during exercise (p  0.08).
EDC  end-diastolic count; relative EaI  EaIEXERCISE/EaIREST; relative ELVI  ELVIEXERCISE/
LVIREST; relative  cardiac output index  COiEXERCISE/COi REST; relative  stroke volume index 
ViEXERCISE/SVi REST; nTTPF time to peak left ventricular filling; RR values normalized for R-R
nterval; VVC  vasculoventricular coupling; VVC ratio  (EaI/ELVI)EXERCISE  (EaI/ELVI)REST; other
bbreviations as in Table 1.eserve on exercise (26). mThe present study examined the pathophysiological mech-
nisms in HFpEF and found marked dynamic (exercise-
nduced) abnormalities in both contractile and diastolic
unction of the LV and a lower peak exercise HR in patients
ith HFpEF. It is possible for an impaired HR response
uring exercise to cause a reduction in exercise capacity as
easured by VO2max, which is largely determined by
ardiac output on exercise and the latter is simply the
roduct of HR and stroke volume. However, in the setting
f a profound slowing of active relaxation and increased LV
assive diastolic stiffness, a greater diastolic filling period
ight be expected to be beneficial.
In this study, despite a longer diastolic filling time, the
elative change in stroke volume was lower in patients
uring submaximal exercise. Impaired HR response may be
consequence of the heart failure because an impaired
hronotropic response (associated with slow HR recovery
fter exercise) is typically present in systolic heart failure and
s in part a manifestation of impaired vagal tone (30), or it
ay be an adaptation to improve diastolic filling. The latter
eems at least plausible because increasing heart rate by
trial pacing has been shown to reduce supine resting stroke
olume and cardiac output in patients with HFpEF (31). It
ill be important to undertake further studies to assess
hether HR plays a causal role in exercise limitation in
FpEF because, if so, it may be amenable to rate responsive
acing.
The patients in this study had a history of hypertension
ut were well treated with antihypertensive medications (in
ost cases including vasodilators); therefore, resting blood
ressure and arterial elastance were not significantly greater
han in the control group. Consistent with previous studies
7), in patients at rest, LV end-systolic elastance (a measure
f contractility or systolic stiffness) tended to be greater in
atients with HFpEF, although this finding did not reach
ignificance. The increase in arterial elastance during exer-
ise tended to be greater in patients with HFpEF versus
ontrol subjects (presumably reflecting a greater increase in
arge artery stiffness). However, although LV end-systolic
lastance almost doubled during exercise in control subjects,
he increase was only 35% in patients with HFpEF; hence,
VC reduced by 33% during exercise in control subjects but
as unchanged in patients with HFpEFs. These findings
ndicate a blunting of the physiological increase in the
ontractile state of the left ventricle on exercise.
The physiological increase in the rate of LV active
elaxation during exercise is a consequence of sympathetic
ctivation, via cAMP-dependent protein kinase A (PKA)-
ediated phosphorylation of key proteins, including tropo-
in I, sarco/endoplasmic reticulum Ca2-ATPase, and titin
32–34). In experimental models, large acute increases in
fterload resulted in an acute impairment of LV active
elaxation (35), with the threshold for this phenomenon
eing lower in the diseased heart, leading to the concept of
relative load” as a determinant of afterload-related impair-
ent of LV active relaxation (36).
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July 28, 2009:402–9 LV Dynamic Abnormalities in HFpEFIn the study of patients with HFpEF described previously
7), handgrip exercise was associated with a substantially
reater increase in LV end-systolic pressure than in control
ubjects, potentially explaining the observed slowing of LV
ctive relaxation. A key coupler of this load-dependent LV
elaxation is troponin I-protein kinase A (TnI-PKA) phos-
horylation (37). It is known that the energy-dependent
rocess of phosphorylation of TnI by PKA decreases myo-
brillar calcium sensitivity (38) and increases the rate at
hich calcium dissociates from troponin C (39), which can
ead to an increased rate of LV relaxation. Indeed, in a study
nvolving transgenic mice in which PKA phosphorylation
ites on TnI were constitutively active, acute aortic constric-
ion led to a lengthening of Tau (an invasive measure of
ctive relaxation) in the wild-type mice but not in the
ransgenic mice (37).
Integrating these observations, we speculate that dynamic
nergy impairment may account for the slowing of LV
ctive relaxation on exercise as well as the failure of LV
ontractile function to increase. To increase the generaliz-
bility of this hypothesis, we avoided positively biasing our
tudy by excluding patients with established causes of
ardiac energy deficiency (ischemic heart disease and diabe-
es) (17,18). Nevertheless, the PCr/ATP ratio was still
ubstantially reduced in patients with HFpEF versus control
ubjects at rest. The lower PCr/ATP ratio in patients
ndicates a reduction of high-energy phosphates reserve at
est (40,41).
Although the time required for acquisition of cardiac
Figure 1 Impaired Myocardial Energetics in Patients With HFpE
(A) Cardiac magnetic resonance (MR) images of a patient with heart failure with p
from the left ventricle. The corresponding peaks of creatine phosphate (PCr) an
phate [ATP]) are labeled. (C) Circles represent individual PCr/gamma-ATP ratio
was significantly reduced in patients with HFpEF compared with healthy controlRS signals precluded the measurement of high energy chosphate status during exercise, it is likely that any basal
nergetic impairment will be exacerbated dynamically. This
xacerbation of dynamic energetic impairment would ex-
lain the prolongation of the energy demanding active
elaxation as manifested by nTTPF. Moreover, the lower
Rs and lesser increases in LV end-systolic elastance may
epresent strategies to limit dynamic cardiac energy de-
ands. The cause for this resting energy deficit may relate
o insulin resistance (42), to impaired mitochondrial func-
ion as a result of aging (43), and to neuroendocrine
ctivation and aberrant substrate metabolism (44). In addi-
ion, increased myocardial fibrosis, as previously reported
erologically in patients with diastolic heart failure (45), may
lso lead to a reduced PCr/ATP ratio in patients with
FpEF. This finding is relevant because in patients with
ypertrophic cardiomyopathy, a reduced PCr/ATP ratio has
een shown to correlate with the presence of a fibrotic area
n the myocardium of the LV (46).
From a clinical perspective, this study has shown that
atients with HFpEF have reduced myocardial energetic
tatus, which provides the rationale to assess the therapeutic
alue of “metabolic agents” (e.g., perhexiline and trimatazi-
ine) that increase cardiac energetic status by altering
ardiac substrate use (47). Indeed, the use of trimetazidine
nd perhexiline have both been shown to be beneficial in
atients with systolic heart failure (48,49). Importantly, we
ave shown that patients with HFpEF have a dynamic
athophysiological process whereby resting parameters may
e comparable with control subjects; however, during exer-
ed ejection fraction (HFpEF) and (B) the corresponding localized 31P MR spectra
gamma-, alpha-, and beta-phosphate (resonances of the adenosine triphos-
tients with HFpEF and in control subjects. The subjects PCr/gamma-ATP ratio
cts (p  0.003).F
reserv
d the
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subjeise, patients with HFpEF have impaired LV active relaxation
a
fi
c
n
m
e
m
S
i
o
r
w
p
b
t
s
s
t
w
e
t
r
c
a
n
d
s
m
e
p
a
r
a
r
e
r
a
t
p
i
p
C
P
s
u
a
c
i
A
T
D
N
A
P
B
d
R
1
1
1
1
1
1
1
408 Phan et al. JACC Vol. 54, No. 5, 2009
LV Dynamic Abnormalities in HFpEF July 28, 2009:402–9nd exhibit no increase in LV end-systolic elastance. This
nding suggests that, in detecting patients with HFpEF, we
annot solely rely on resting parameters and that we perhaps
eed to consider some form of exercise testing, such as
etabolic exercise testing as advocated by Coats et al. (9) or
xercise radionuclide ventriculography scans, to detect abnor-
al LV relaxation during exercise.
tudy limitations. Our radionuclide exercise protocol
nvolved asking subjects to maintain an HR that was 50%
f HR reserve above their resting HR. Because this HR
eserve was calibrated to peak HR rate, the absolute
orkload in patients was lower. To have compared
atients at the same workload would be inappropriate
ecause this comparison would represent a greater rela-
ive workload in patients. Moreover, most changes in
troke volume occur in the first part of exercise, with
ubsequent increases in cardiac output being principally
he result of increases in HR (50).
A small proportion of patients were on beta-blockers,
hich may have affected their cardiovascular response to
xercise; however, when these patients were excluded from
he analysis, the findings and the level of significance
emained unchanged. In addition, some patients were on
alcium blockers; however, these drugs were all peripherally
cting (dihydropyridine for hypertension) and therefore are
ot expected to affect the myocardium directly.
Ideally, we would have liked to measure cardiac energetics
uring exercise; however, the performance of cardiac MRS
tudies during exercise is currently quite challenging and
ore so if we tried to replicate the same dynamic leg
xercise in the confinement of a MR scanner. A number of
roblems, such as acquisition at greater heart rates, shorter
cquisition times, voxel specificity, pulse design, and shorter
epetition times, are currently being addressed by our group
nd other groups around the world.
The use of MRS and radionuclide studies also requires a
egular rhythm; thus, patients with atrial fibrillation were
xcluded from the study. In contrast, the strength of
adionuclide studies is their increasing temporal resolution
t greater HRs. This obviates the confounding E:A fusion
hat is frequently experienced with exercise echocardiogra-
hy. Radionuclide studies are thus not subject to systemat-
cally biasing mechanistic HFpEF toward a subgroup of
atients without E:A fusion on exercise.
onclusions
atients with HFpEF have reduced cardiac energetic re-
erves which, when exacerbated dynamically, may contrib-
te to the abnormal LV active relaxation during exercise and
lack of increase in LV end-systolic elastance. In addition,
hronotropic response is markedly impaired during exercise
n patients.
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